Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Factor Xa Inhibitor [EPC]

Known as: Factor 10a Inhibitor, Activated Factor X Inhibitor, Activated Factor 10 Inhibitor 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Antithrombin III
Factor Xa inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
Essentials The value of thrombin generation assay (TGA) in monitoring direct oral anticoagulants (DOAC) is not well defined. TGA… Expand
2016
2016
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the… Expand
2015
2015
Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management
PurposeWe report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban… Expand
  • figure 2
  • figure 1
Review
2015
Review
2015
A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After…
Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in… Expand
  • figure 1
  • table 1
  • table 2
2015
2015
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial…
OBJECTIVES The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for… Expand
  • table 1
  • table 2
2014
2014
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip… Expand
  • table 1
  • table 2
Highly Cited
2013
Highly Cited
2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
OBJECTIVES The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Review
2013
Review
2013
The Cost‐Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low‐Molecular‐Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery
Major orthopedic surgery is associated with a high risk of venous thromboembolism (VTE). Anticoagulants are recommended to… Expand
2013
2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE